Aesthetic Improvement of Facial Rhytids Using Injectables
NCT: NCT07383766 · COMPLETED
Brief Summary
Revanesse® Renew™+ (Prollenium Medical Technologies Inc.) is a non-crosslinked HA skin booster that combines low- and high-molecular-weight HA at a concentration of 14 mg/mL in a sterile aqueous gel for intradermal injection7. This dual-weight formulation provides both rapid hydration and sustained moisture retention, improving dermal suppleness and promoting subtle textural refinement through physiologic hydration rather than volumization. The present study is designed to compare biweekly and monthly treatment schedules of Revanesse® Renew™+, assessing clinical efficacy, objective biophysical markers, and participant-reported outcomes to inform evidence-based treatment protocols in aesthetic medicine.
Frequently Asked Questions
What is Aesthetic Improvement of Facial Rhytids Using Injectables?
Aesthetic Improvement of Facial Rhytids Using Injectables is a clinical trial registered under NCT07383766. Current status: COMPLETED.
What is the status of NCT07383766?
The current status of NCT07383766 (Aesthetic Improvement of Facial Rhytids Using Injectables) is: COMPLETED.
When did Aesthetic Improvement of Facial Rhytids Using Injectables start?
Aesthetic Improvement of Facial Rhytids Using Injectables started on 2026-03-14.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.